Oculis Holding AG

NasdaqGM OCS

Oculis Holding AG Cash and Short-Term Investments for the year ending December 31, 2023: USD 108.86 M

Oculis Holding AG Cash and Short-Term Investments is USD 108.86 M for the year ending December 31, 2023, a 408.76% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
  • Oculis Holding AG Cash and Short-Term Investments for the year ending December 31, 2022 was USD 21.40 M, a -57.82% change year over year.
  • Oculis Holding AG Cash and Short-Term Investments for the year ending December 31, 2021 was USD 50.72 M, a 806.80% change year over year.
  • Oculis Holding AG Cash and Short-Term Investments for the year ending December 31, 2020 was USD 5.59 M.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
NasdaqGM: OCS

Oculis Holding AG

CEO Dr. Riad Sherif M.B.A., M.D.
IPO Date May 18, 2021
Location Switzerland
Headquarters Bahnhofstrasse 7
Employees 36
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

StockViz Staff

January 15, 2025

Any question? Send us an email